Chronic Pain News and Research

RSS

New study on pain-relieving effect of transcutaneous Vagus Nerve Stimulation

The medical device company cerbomed cooperated with the Clinic for Psychiatry and Psychotherapy of the University of Regensburg 2010 on a randomized, controlled study into somatosensory pain processing. The study, lead by Prof. Dr. Peter Eichhammer and Dr. Volker Busch, aimed to judge the pain-relieving effect of transcutaneous Vagus Nerve Stimulation (t-VNS).

25 Jan 2011

St. Jude Medical's Athena programmer DBS system receives Australian TGA approval

St. Jude Medical, Inc., a global medical device company, today announced regulatory approval from the Australian Therapeutic Goods Administration (TGA) of its Athena™ programmer, a deep brain stimulation (DBS) therapy management system.

24 Jan 2011

BDSI refutes MonoSol's patent infringement claims relating to BEMA Buprenorphine

BioDelivery Sciences International, Inc. today responded to a process patent infringement lawsuit filed and recently served against the Company and certain co-defendants by MonoSol Rx, LLC. The purpose in responding at this time is for BDSI to strongly refute MonoSol's claims and to assure BDSI stockholders that the Company remains focused on vigorously progressing its pipeline and not allowing this claim to present a distraction.

24 Jan 2011

Anaesthetising an arm affects brain activity and rapidly impairs body perception

An Inserm research team in Toulouse, led by Dr Stein Silva (Inserm Unit 825 "Brain imaging and neurological handicaps"), working with the "Modelling tissue and nociceptive stress" Host Team (MATN IFR 150), were interested in studying the illusions described by many patients under regional anaesthetic.

20 Jan 2011

Forest Laboratories third quarter net sales increase 6.7% to $1,063.9 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.11 in the third quarter of fiscal 2011 after taking a charge for a new product licensing fee of $66.1 million or $0.23 per share, net of tax.

18 Jan 2011

Diamyd commences NP2 Enkephalin Phase II trial to reduce cancer pain

Diamyd has dosed the first subject in a Phase II clinical trial in the United States evaluating the ability of the candidate drug NP2 Enkephalin to reduce cancer pain.

17 Jan 2011

20% of cancer survivors experience chronic pain: Study

Surviving cancer may also mean surviving pain, according to a study by the University of Michigan Health System showing 20 percent of cancer survivors at least two years post diagnosis have current cancer-related chronic pain.

13 Jan 2011

NSAIDs raise risk of heart disease: Study

A new study published online in the British Medical Journal explores the relative safety of non-steroidal anti-inflammatory medications (NSAIDs), commonly used to treat joint and muscle aches and pain and concludes that NSAIDs significantly increase the risk of cardiovascular events in patients who take them regularly.

12 Jan 2011

UnitedHealthcare selects Millennium as participating provider of pain management services

Millennium Laboratories, a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain, announced it will provide pain management and therapeutic drug monitoring services to physicians participating in UnitedHealthcare's national care provider network.

12 Jan 2011

Lightning Process training course tops in survey by ME/ CFS

A revolutionary self training course has emerged top in a survey conducted by the Sussex and Kent ME/ CFS Society.

12 Jan 2011

Pain services severely inadequate: report

The Patients Association has urged the Government to create a clear care pathway for chronic pain services throughout the National Health Service. This came in after a survey of more than 4,000 patients revealed significant shortcomings in care.

11 Jan 2011

General anaesthesia brings reversible coma and not sleep: Study

Anaesthesia has been one of the greatest gifts of science and use of general anaesthesia is a routine part of surgical operations at hospitals and medical facilities around the world. However precise biological mechanisms of the drugs’ effects on the brain are only now being analyzed. In a review article published this week in the New England Journal of Medicine, scientists have tried to analyze a range of disciplines, including neuroscience and sleep medicine to understand how anaesthesia actually works.

2 Jan 2011

NDA resubmitted for DURECT's ORADUR technology based REMOXY

DURECT Corporation today reported that King Pharmaceuticals, Inc. and Pain Therapeutics, Inc. have announced that King has resubmitted a New Drug Application (NDA) for REMOXY® to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter received by Pain Therapeutics in December 2008. This is a Class 2 resubmission with a six month review cycle.

28 Dec 2010

Spinal Botox injection reduces pain

Botulinum neurotoxin type A (BoNT/A)—better known as Botox—reduces responses to an inflammation-related pain stimulus when injected into the spinal canal in mice, reports a study in the January issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

22 Dec 2010

Scientists suggest targeting ion channels could offer effective pain relief

University at Buffalo neuroscience researchers conducting basic research on ion channels have demonstrated a process that could have a profound therapeutic impact on pain.

20 Dec 2010

Pico-Tesla commences pilot study of Magneceutical Therapy in fibromyalgia patients

Pico-Tesla, The Magneceutical® Company, announced that it has commenced a randomized, double-blind, placebo-controlled pilot study of 30 patients who have fibromyalgia. The pilot study seeks to determine whether the application of magnetic fields generated by Pico-Tesla's patented Resonator™ system can be effective as an adjunctive therapy to oral medications in ameliorating the symptoms of fibromyalgia.

16 Dec 2010

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

Multiple myeloma, a type of blood cancer in which malignant plasma cells are overproduced in the bone marrow, has led to an estimated 20,000 new diagnoses and 11,000 deaths in 2010. Patients with the disease, who have already failed previous treatments, may be considered for a currently enrolling Phase II study, examining a unique drug combination.

14 Dec 2010

Depression drug appears effective in reducing pain associated with breast cancer treatment

A drug commonly used to treat depression and anxiety disorder was effective at reducing joint and muscle pain associated with a breast cancer treatment, according to a study from the University of Michigan Comprehensive Cancer Center.

12 Dec 2010

31-year-old mother with Gorham-Stout syndrome goes home with virtually rebuilt spine

Laurie Harms, Los Angeles, feared she'd never hold her infant daughter, Sky, again. A devastating and extremely rare bone-eroding disease - Gorham-Stout syndrome - had left the 31-year-old crumpled in a hospital bed - her neck broken, arms limp and useless, and voice muted by tubes.

10 Dec 2010

BDSI initiates dosing in BEMA Buprenorphine Phase 3 clinical program for chronic pain

BioDelivery Sciences International, Inc. today announced the enrollment and dosing of the first patient in its Phase 3 clinical program evaluating the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain.

9 Dec 2010

Chronic Pain News and Research

New study on pain-relieving effect of transcutaneous Vagus Nerve Stimulation

St. Jude Medical's Athena programmer DBS system receives Australian TGA approval

BDSI refutes MonoSol's patent infringement claims relating to BEMA Buprenorphine

Anaesthetising an arm affects brain activity and rapidly impairs body perception

Forest Laboratories third quarter net sales increase 6.7% to $1,063.9 million

Diamyd commences NP2 Enkephalin Phase II trial to reduce cancer pain

20% of cancer survivors experience chronic pain: Study

NSAIDs raise risk of heart disease: Study

UnitedHealthcare selects Millennium as participating provider of pain management services

Lightning Process training course tops in survey by ME/ CFS

Pain services severely inadequate: report

General anaesthesia brings reversible coma and not sleep: Study

NDA resubmitted for DURECT's ORADUR technology based REMOXY

Spinal Botox injection reduces pain

Scientists suggest targeting ion channels could offer effective pain relief

Pico-Tesla commences pilot study of Magneceutical Therapy in fibromyalgia patients

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

Depression drug appears effective in reducing pain associated with breast cancer treatment

31-year-old mother with Gorham-Stout syndrome goes home with virtually rebuilt spine

BDSI initiates dosing in BEMA Buprenorphine Phase 3 clinical program for chronic pain

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News